M
Michail Ignatiadis
Researcher at Université libre de Bruxelles
Publications - 151
Citations - 12847
Michail Ignatiadis is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 44, co-authored 132 publications receiving 10017 citations. Previous affiliations of Michail Ignatiadis include Institut Jules Bordet & University of Crete.
Papers
More filters
Journal ArticleDOI
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Roberto Salgado,Carsten Denkert,Sandra Demaria,Nicolas Sirtaine,Frederick Klauschen,Giancarlo Pruneri,Stephan Wienert,G. Van den Eynden,Frederick L. Baehner,Frédérique Penault-Llorca,E. A. Perez,E. A. Thompson,William Fraser Symmans,Andrea L. Richardson,Jane E. Brock,Carmen Criscitiello,Helen Bailey,Michail Ignatiadis,Giuseppe Floris,Joseph A. Sparano,Zuzana Kos,Torsten O. Nielsen,David L. Rimm,Kimberly H. Allison,Jorge S. Reis-Filho,Sibylle Loibl,Christos Sotiriou,Giuseppe Viale,Sunil S. Badve,Sylvia Adams,Karen Willard-Gallo,Sherene Loi +31 more
TL;DR: Current data on the clinical validity and utility of TILs in BC are reviewed in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections.
Journal ArticleDOI
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
Pratyaksha Wirapati,Christos Sotiriou,Susanne Kunkel,Pierre Farmer,Sylvain Pradervand,Benjamin Haibe-Kains,Christine Desmedt,Michail Ignatiadis,Thierry Sengstag,Frédéric Schütz,Darlene R. Goldstein,Darlene R. Goldstein,Darlene R. Goldstein,Martine Piccart,Mauro Delorenzi +14 more
TL;DR: This meta-analysis of publicly available breast cancer gene expression and clinical data reveals connections between traditional prognostic factors, expression-based subtyping, and prognostic signatures, highlighting the important role of proliferation in breast cancer prognosis.
Journal ArticleDOI
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Chunyan Gu-Trantien,Sherene Loi,Soizic Garaud,Carole Equeter,Myriam Libin,Alexandre de Wind,Marie Ravoet,Hélène Le Buanec,Catherine Sibille,Germain Manfouo-Foutsop,Isabelle Veys,Benjamin Haibe-Kains,Sandeep Singhal,Stefan Michiels,Françoise Rothé,Roberto Salgado,Hugues Duvillier,Michail Ignatiadis,Christine Desmedt,Dominique Bron,Denis Larsimont,Martine Piccart,Christos Sotiriou,Karen Willard-Gallo +23 more
TL;DR: The identification of CD4⁺ Tfh cells in breast cancer suggests that they are an important immune element whose presence in the tumor is a prognostic factor.
Journal ArticleDOI
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Lucy R. Yates,Moritz Gerstung,Stian Knappskog,Christine Desmedt,Gunes Gundem,Peter Van Loo,Turid Aas,L. Alexandrov,Denis Larsimont,Helen Davies,Yang Li,Young Seok Ju,Manasa Ramakrishna,Hans Kristian Haugland,Peer Kaare Lilleng,Serena Nik-Zainal,Stuart McLaren,Adam Butler,Sancha Martin,Dominic D Glodzik,Andrew Menzies,Keiran Raine,Jonathan Hinton,David T. Jones,Laura Mudie,Bing B Jiang,Delphine Vincent,April Greene-Colozzi,Pierre-Yves Adnet,Aquila Fatima,Marion Maetens,Michail Ignatiadis,Michael R. Stratton,Christos Sotiriou,Andrea L. Richardson,Per Eystein Lønning,David C. Wedge,Peter J. Campbell +37 more
TL;DR: To understand the subclonal structure of primary breast cancer, whole-genome and targeted sequencing was applied to multiple samples from each of 50 patients' tumors, finding thatLandmarks of disease progression arose within detectable subclones of antecedent lesions.
Journal ArticleDOI
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
François-Clément Bidard,François-Clément Bidard,Dieter Peeters,Tanja Fehm,Franco Nolè,Rafael Gisbert-Criado,Dimitris Mavroudis,Salvatore Grisanti,Daniele Generali,Jose Ja Garcia-Saenz,Justin Stebbing,Carlos Caldas,Paola Gazzaniga,Luis Manso,Rita Zamarchi,Angela Fernandez de Lascoiti,Leticia De Mattos-Arruda,Michail Ignatiadis,Ronald Lebofsky,Steven Van Laere,Steven Van Laere,Franziska Meier-Stiegen,Maria Teresa Sandri,Jose Vidal-Martinez,Eleni Politaki,Francesca Consoli,Alberto Bottini,Eduardo Díaz-Rubio,Jonathan Krell,Sarah-Jane Dawson,Cristina Raimondi,Annemie Rutten,Wolfgang Janni,Elisabetta Munzone,Vicente Carañana,Sofia Agelaki,Camillo Almici,Luc Dirix,Erich-Franz Solomayer,Laura Zorzino,Helene Johannes,Jorge S. Reis-Filho,Klaus Pantel,Jean-Yves Pierga,Jean-Yves Pierga,Stefan Michiels +45 more
TL;DR: These data confirm the independent prognostic effect of CTC count on progression-free survival and overall survival and also improves the prognostication of metastatic breast cancer when added to full clinicopathological predictive models, whereas serum tumour markers do not.